Quarterly report pursuant to Section 13 or 15(d)

Business and Liquidity (Details)

v2.4.0.8
Business and Liquidity (Details) (USD $)
0 Months Ended 3 Months Ended 6 Months Ended
Feb. 22, 2013
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
item
Jun. 30, 2012
Dec. 31, 2012
Dec. 31, 2011
Business and Liquidity              
Period since the entity has begun commercialization outside the United States of its newest product, RenalGuard       5 years      
Number of operating segments       1      
Loss from operations   $ (1,286,000) $ (966,000) $ (2,356,000) $ (2,135,000)    
Cash used in operations       2,870,000 1,464,000    
Cash and cash equivalents   1,128,000 997,000 1,128,000 997,000 258,000 2,585,000
Additional capital $ 4,040,000